Table 3 Overview of incidence of... | American Society of Hematology

Table 3

Overview of incidence of nonresponse in CLL in selected first-line treatment trial cohorts and treatment approaches^5,9-11,62,63

Trial	A	Clb	B	F	FC	FCR
UKCLL4⁹ (n = 777)		28		20	6
Clb vs Benda⁶³ (n = 314)		69	32
CAM307⁶² (n = 297)	17	45
GCLLSG CLL4¹⁰ (n = 375)				17	5
ECOG³⁹ (n = 278)				41	26
GCLLSG CLL8⁵, n = 817 (Binet C)					20 (23)	10 (16)
MDACC⁶ (n = 300; nonrandomized)						5

Trial	A	Clb	B	F	FC	FCR
UKCLL4⁹ (n = 777)		28		20	6
Clb vs Benda⁶³ (n = 314)		69	32
CAM307⁶² (n = 297)	17	45
GCLLSG CLL4¹⁰ (n = 375)				17	5
ECOG³⁹ (n = 278)				41	26
GCLLSG CLL8⁵, n = 817 (Binet C)					20 (23)	10 (16)
MDACC⁶ (n = 300; nonrandomized)						5

A indicates alemtuzumab; Clb, chlorambucil; B, bendamustine; F, fludarabine; C, cyclophosphamide; and R, rituximab.